Thromb Haemost 1991; 66(01): 123-132
DOI: 10.1055/s-0038-1646380
Review Article
Schattauer GmbH Stuttgart

Structure of Vitronectin and its Biological Role in Haemostasis

Klaus T Preissner
,
Dieter Jenne
Further Information

Publication History

Publication Date:
25 July 2018 (online)

 
  • References

  • 1 Holmes R. Preparation from human serum of an alpha-one protein which induces the immediate growth of unadapted cells in vitro. . J Cell Biol 1967; 32: 297-308
  • 2 Hayman EG, Engvall E, A'Hearn E, Barnes D, Pierschbacher M, Ruoslahti E. Cell attachment of replicas of SDS polyacrylamide gels reveals two adhesive plasma proteins. J Cell Biol 1982; 95: 20-23
  • 3 Jenne D, Stanley KK. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985; 4: 3153-3157
  • 4 Preissner KT, Heimburger N, Anders E, Müller-Berghaus G. Physicochemical, immunochemical and functional comparison of human S-protein and vitronectin. Evidence for the identity of both plasma proteins. Biochem Biophys Res Commun 1986; 134: 951-956
  • 5 Tomasini BR, Mosher DF. On the identity of vitronectin and S-protein: Immunological crossreactivity and functional studies. Blood 1986; 68: 737-742
  • 6 Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985; 4: 2519-2524
  • 7 Sato R, Komine Y, Imanaka T, Takano TJ. Monoclonal antibody EMR 1a/212D recognizing site of deposition of extracellular lipid in atherosclerosis. Isolation and characterization of a cDNA clone for the antigen. J Biol Chem 1990; 265: 21232-21236
  • 8 Jenne D, Stanley KK. Nucleotide sequence and organization of the human S-protein gene: repeating peptide motifs in the "pexin" family and a model for their evolution. Biochemistry 1987; 26: 6735-6742
  • 9 Patthy L. Detecting distant homologies of mosaic proteins. Analysis of the sequences of thrombomodulin, thrombospondin complement components C9, C8-alpha and C8-β, vitronectin and plasma cell membrane glycoprotein PC-1. J Mol Biol 1988; 202: 689-696
  • 10 Fryklund L, Sievertsson H. Primary structure of somatomedin B - A growth hormone-dependent serum factor with protease inhibiting activity. FEBS Lett 1978; 87: 55-60
  • 11 Suzuki S, Pierschbacher MD, Hayman EG, Nguyen K, Ohgren Y, Ruoslahti E. Domain structure of vitronectin. J Biol Chem 1984; 259: 15307-15314
  • 12 Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: A versatile cell recognition signal. Cell 1986; 44: 517-518
  • 13 Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemostas 1988; 59: 1-6
  • 14 Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 1987; 262: 17703-17711
  • 15 Bale MD, Wohlfahrt LA, Mosher DF, Tomasini B, Sutton RC. Identification of vitronectin as a major plasma protein absorbed on polymer surfaces of different copolymer composition. Blood 1989; 74: 2698-2706
  • 16 Hayman EG, Pierschbacher MD, Suzuki S, Ruoslahti E. Vitronectin - a major cell attachment-promoting protein in fetal bovine serum. Exp Cell Res 1985; 160: 245-258
  • 17 Underwood PA, Bennett FA. A comparison of the biological activities of the cell-adhesive proteins vitronectin and fibronectin. J Cell Sci 1989; 93: 641-649
  • 18 Ruoslahti E, Suzuki S, Hayman EG, Ill CR, Pierschbacher MD. Purification and characterization of vitronectin. Methods Enzymol 1987; 144: 430-437
  • 19 Jenne D, Hille A, Stanley KK, Huttner WB. Sulfation of two tyrosine-residues in human complement S-protein (vitronectin). Eur J Biochem 1989; 185: 391-395
  • 20 Sane DC, Moser TL, Pippen AMM, Parker CJ, Achyuthan KE, Greenberg CS. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res-Commun 1988; 157: 115-120
  • 21 Skoorstengaard K, Halkier T, Hojrup P, Mosher D. Sequence location of a putative transglutaminase cross-linking site in human vitronectin. FEBS Lett 1990; 262: 269-274
  • 22 Gebb C, Hayman EG, Engvall E, Ruoslahti E. Interaction of vitronectin with collagen. J Biol Chem 1986; 261: 16698-16703
  • 23 Izumi M, Shimo-Oka T, Morishita N, Ii I, Hayashi M. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct 1988; 13: 217-225
  • 24 Hunt LT, Barker WC, Chen HR. A domain structure common to hemopexin, vitronectin, interstitial collagenase, and a collagenase homologue. Prot Seq Data Anal 1987; 1: 21-26
  • 25 Smith A, Tatum FM, Muster P, Burch MK, Morgan T. Importance of ligand-induced conformational changes in hemopexin for receptor-mediated heme transport. J Biol Chem 1988; 263: 5224-5229
  • 26 Preissner KT, Müller-Berghaus G. Neutralisation and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 1987; 262: 12247-12253
  • 27 Barnes DW, Reing JE, Amos B. Heparin-binding properties of human serum spreading factor. J Biol Chem 1985; 260: 9117-9122
  • 28 Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 1989; 990: 101-108
  • 29 Tomasini BR, Mosher DF. Vitronectin. Prog Hemost Thromb 1990 10. (in press)
  • 30 Dahlbôck B, Podack ER. Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry 1985; 24: 2368-2374
  • 31 Preissner KT, Wassmuth R, Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 1985; 231: 349-355
  • 32 Hildebrand A, Preissner KT, Müller-Berghaus G, Teschemacher H. A novel beta-endorphin binding protein. Complement S protein (= vitronectin) exhibits specific non-opioid binding sites for β-endorphin upon interaction with heparin or surfaces. J Biol Chem 1989; 264: 15429-15434
  • 33 Tomasini B, Mosher DF. Conformational states of vitronectin: Prefereal expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea. Blood 1988; 72: 903-912
  • 34 Sane DC, Moser TL, Parker CJ, Seiffert D, Loskutoff DJ, Greenberg CS. Highly sulfated glycosaminoglycans augment the cross-linking of vitronectin by guinea pig liver transglutaminase. Functional studies of the cross-linked vitronectin multimers. J Biol Chem 1990; 265: 3543-3548
  • 35 Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Müller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498
  • 36 Barnes DW, Reing J. Human spreading factor: Synthesis and response by HepG2 hepatoma cells in culture. J Cell Physiol 1985; 125: 207-214
  • 37 Conlan MG, Tomasini BR, Schultz RL, Mosher DF. Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood 1988; 72: 185-190
  • 38 Kubota K, Hayashi M, Oishi N, Sakaki Y. Polymorphism of the human vitronectin gene causes vitronectin blood type. Biochem Biophys Res Commun 1990; 167: 1355-1360
  • 39 Tollefsen DM, Weigel CJ, Kabeer MH. The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem 1990; 265: 9778-9781
  • 40 Podack ER, Müller-Eberhard HJ. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9908-9914
  • 41 McGuire EA, Peacock ME, Inhorn R, Siegel NR, Tollefsen DM. Phosphorylation of vitronectin by a protein kinase in human plasma. J Biol Chem 1988; 263: 1942-1945
  • 42 Korc-Grodzicki B, Tauber-Finkelstein M, Chain D, Shaltiel S. Vitronectin is phosphorylated by a cAMP-dependent protein kinase released by activation of human platelets with thrombin. Biochem Biophys Res Commun 1988; 157: 1131-1138
  • 43 Shaffer MC, Foley TP, Barnes DW. Quantitation of spreading factor in human biologic fluids. J Lab Clin Med 1984; 103: 783-791
  • 44 Preissner KT, Holzhüter S, Justus C, Müller-Berghaus G. Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989; 74: 1989-1996
  • 45 Parker CJ, Stone OL, White VF, Bernshaw NJ. Vitronectin (S-protein) is associated with platelets. Br J Haematol 1989; 71: 245-252
  • 46 Kanz L, Löhr GW, Preissner KT. Identification of human megakaryocyte vitronectin/S-protein.. Blood 1988; 72 (Suppl. 1) 327a
  • 47 Hetland G, Pettersen HB, Mollnes TE, Johnson E. S-protein is synthesized by human monocytes and macrophages in vitro. . Scand J Immunol 1989; 29: 15-21
  • 48 Gladson CL, Seegmiller JE, Smith JW, Klier G, Cheresh DA. Glioblastoma cells synthesize and secrete the adhesive protein vitronectin. JExp Neuro 1990; 49: 33
  • 49 Hayman EG, Pierschbacher MD, Ohgren Y, Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci USA 1983; 80: 4003-4007
  • 50 Dahlbôck K, Löfberg H, Alumets J, Dahlbôck B. Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers. J Invest Dermatol 1989; 92: 727-733
  • 51 Falk RJ, Podack E, Dalmasso AP, Jennette JC. Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol 1987; 127: 182-190
  • 52 Guettier C, Hinglais N, Bruneval P, Kazatchkine M, Bariety J, Camilleri J-P. Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat 1989; 414: 309-313
  • 53 Bariety J, Hinglais N, Bhakdi S, Mandet C, Rouchon M, Kazatchkine MD. Immunohistochemical study of complement S protein (vitronectin) in normal and diseased human kidneys: Relationship to neoantigens of the C5b-9 terminalcomplex. J Clin Exp Immunol 1989; 75: 76-81
  • 54 Lane DA, Flynn AM, Pejler G, Lindahl U, Choay J, Preissner KT. Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J Biol Chem 1987; 262: 16343-16349
  • 55 Kemkes-Matthes B, Preissner KT, Langenscheidt F, Matthes KJ, Müller-Berghaus G. S protein/vitronectin in chronic liver diseases: Correlations with serum cholinesterase, coagulation factor X and complement component C3. Eur J Haematol 1987; 39: 161-165
  • 56 Baetscher M, Pumplin DW, Bloch RJ. Vitronectin at sites of cell-substrate contact in cultures of rat myotubes. J Cell Biol 1986; 103: 369-378
  • 57 Hynes RO. Integrins: A family of cell surface receptors. Cell 1987; 48: 549-54
  • 58 Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 238: 491-497
  • 59 Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-953
  • 60 Ruoslahti E. Fibronectin and its receptors. Ann Rev Biochem 1988; 57: 375-413
  • 61 Seiffert D, Wagner NN, Loskutoff DJ. Serum-derived vitronectin influences the pericellular distribution of type-1 plasminogen-activator inhibitor. J Cell Biol 1990; 111: 1283-1291
  • 62 Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987; 84: 6471-6475
  • 63 Preissner KT, Anders E, Grulich-Henn J, Müller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood 1988; 71: 1581-1589
  • 64 Dejana E, Colella S, Conforti G, Abbadini M, Gaboli M, Marchisio PC. Fibronectin and vitronectin regulate the organization of their respective Arg-Gly-Asp adhesion receptors in cultured endothelial cells. J Cell Biol 1988; 107: 1215-1223
  • 65 Lam SCT, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem 1989; 264: 3742-3749
  • 66 Thiagarajan P, Kelly KL. Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 1988; 263: 3035-3038
  • 67 Lawler J, Hynes O. An integrin receptor on normal and thromboasthenic platelets that binds thrombospondin. Blood 1989; 74: 2022-2027
  • 68 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as prototypic adhesion receptor. Prog Hemost Thromb 1989; 9: 117-156
  • 69 Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1990; 83: 288-297
  • 70 Woods A, Couchman JR. Focal adhesions and cell-matrix interactions. Collagen Rel Res 1988; 8: 155-182
  • 71 Preissner KT, Sié P. Modulation of heparin cofactor II function by S protein (vitronectin) and formation of a ternary S protein-thrombin-heparincofactor II complex. Thromb Haemostas 1988; 60: 399-406
  • 72 Elenius K, Salmivirta M, Inki P, Mali M, Jalkanen M. Binding of human syndecan to extracellular-matrix proteins. J Biol Chem 1990; 265: 17837-17843
  • 73 Murphy-Ullrich JE, Mosher DF. Interactions of thrombospondin with endothelial cells: Receptor-mediated binding and degradation. J Cell Biol 1987; 105: 1603-1611
  • 74 Damus PS, Hicks M, Rosenberg RD. A generalized view of heparin'santi-coagulant action. Nature 1973; 246: 355-357
  • 75 Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986
  • 76 Podack ER, Dahlbôck B, Griffin JH. Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. J Biol Chem 1986; 261: 7387-7392
  • 77 Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 1988; 13: 281-292
  • 78 Akama T, Yamada KM, Seno N, Matsumoto I, Kono I, Kashiwagi H, Funaki T, Hayashi M. Immunological characterization of human vitronectin and its binding to glycosaminoglycans. J Biochem 1986; 100: 1343-1351
  • 79 Preissner KT. Physiological role of vessel wall related antithrombotic mechanisms: Contribution of endogenous and exogenous heparin-like components to the anticoagulant potential of the endothelium. Haemost 1990; 20: 30-49
  • 80 Ill CR, Ruoslahti E. Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 1985; 260: 15610-15615
  • 81 Jenne D, Hugo F, Bhakdi S. Interaction of complement S-protein with thrombin-antithrombin complexes: A role for the S-protein in haemostasis. Thromb Res 1989; 38: 401-412
  • 82 Preissner KT, Zwicker L, Müller-Berghaus G. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J 1987; 243: 105-111
  • 83 Rovelli G, Stone SR, Preissner KT, Monard D. Specific interaction of vitronectin with the cell-secreted protease inhibitor glia-derived nexin (GDN) and the GDN-thrombin complex. Eur J Biochem 1990; 192: 797-803
  • 84 Stanley KK. Homology with hemopexin suggests a possible scavenging function of S-protein/vitronectin. FEBS Lett 1986; 199: 249-253
  • 85 Tomasini BR, Mosher DF, Owen MC, Fenton JW. Conformational lability of vitronectin: Induction of an antigenic change by γ-thrombin-serpin complexes and by proteolytically modified thrombin. Biochemistry 1989; 28: 832-842
  • 86 Pepper DS, Banhegyi D, Cash JD. The different forms of antithrombin III in serum. Thrombos Haemostas 1977; 38: 494-503
  • 87 Marciniak E, Gora-Maslak G. High molecular weight forms of antithrombin III complexes in blood. Thromb Haemostas 1983; 49: 32-36
  • 88 Shifman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257: 3243-3248
  • 89 Bar-Shavit R, Sabbah V, Lampugnani MG, Marchisio PC, Fenton II JW, Vlodavski I, Dejana E. An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol 1990; 112: 335-344
  • 90 Bar-Shavit R, Wilner GD. Mediation of cellular events by thrombin. Int Rev Exp Path 1986; 29: 213-241
  • 91 Loskutoff DJ, Sawdey M, Mimuro J. Type-1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115
  • 92 Levin EG, Santell L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol 1987; 105: 2543-2549
  • 93 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-728
  • 94 Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques E-P, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461
  • 95 Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen-activator inhibitor-1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 242: 125-128
  • 96 Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type-1 plasminogen-activator inhibitor and prevents its interaction with extracellular-matrix - evidence that the protein is vitronectin. J Biol Chem 1989; 264: 936-939
  • 97 Salonen E-M, Vaheri A, Pöllônen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989; 264: 6339-6343
  • 98 Mimuro J, Loskutoff DJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem 1989; 264: 5058-5063
  • 99 Ciambrone GJ, McKeown-Longo PJ. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J Cell Biol 1990; 11: 2183-2195
  • 100 Ehrlich HJ, Keijer J, Preissner KT, Klein Gebbink R, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30: 1021-1028
  • 101 Ehrlich HJ, Klein Gebbink R, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-13035
  • 102 Radtke K-P, Wenz KH, Heimburger N. Isolation of plasminogen activtor inhibitor-2 (PAI-2) from human placenta. Biol Chem Hoppe-Seyler 1990; 371: 1019-1027
  • 103 Preissner KT. Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator. Biochem Biophys Res Commun 1990; 168: 966-971
  • 104 Tschopp J, Masson D, Schôfer S, Peitsch M, Preissner KT. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988; 27: 4103-4109